UBS rates VIAC as buy.
3-Nov-06 UBS Upgrade FROM: Reduce TO: Buy
ViaCell, Inc., a biotechnology company, engages in the research, development, and commercialization of cellular therapies in the United States and Singapore. It develops a pipeline of proprietary umbilical cord blood-derived and adult-derived stem cell product candidates as treatments for cancer, cardiac disease, and diabetes. The company conducts a Phase I clinical trial of CB001, its lead umbilical cord blood-derived stem cell therapy product candidate as a treatment for hematopoietic stem cell reconstitution in patients affected by various cancers. It also sells ViaCord, a product offering through which expectant families can preserve their baby’s umbilical cord blood for possible future medical use. In addition, the company develops ViaCytesm, its investigational product candidate that intended to expand reproductive choices for women through the cryopreservation of human unfertilized eggs. It has an agreement with Stem Cell Internal Venture of Centocor Research & Development, Inc. to collaborate on studying a treatment for cardiac disease.
VIAC is trading up 7% to $4.22 in afternoon trading with double volume.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment